In a transcript published Sept. 8, 2026, from the Wells Fargo 21st Annual Healthcare Conference, moderated by Wells Fargo biotech analyst Yanan Zhu, Atrium Therapeutics said its RNA-based heart programs are advancing, with the company preparing to dose the first patient in its lead PRKAG2 study.
Atrium, which spun out of Avidity in late 2024 following the Avidity-Novartis transaction, has passed its six-month mark as an independent company. Its cash runway extends through mid-2028, excluding potential future milestones, while free cash flow burn is about $57 million annually. The company reported a market capitalization of $243 million, trailing-12-month revenue of $36 million, and a current ratio of 8.73.
Executives participating in the session included CEO Kath Gallagher, CFO Brendan Winslow and CMO Steve Hughes. The company's partners include Bristol Myers Squibb, Eli Lilly and Novartis. Atrium received $30 million from Bristol Myers Squibb during its first six months as an independent company, tied to development-candidate and lead-candidate targets. The BMS collaboration provides up to $2.2 billion in milestones plus low double-digit royalties across up to five cardiovascular targets.
The lead program, Corventis, targets PRKAG2 syndrome, an autosomal dominant gain-of-function disease associated with arrhythmogenic and hypertrophic cardiomyopathy. Symptoms typically begin in the teens or early 20s, and literature cites an 8% to 10% risk of sudden cardiac death. Atrium said it has identified close to 2,000 people with the mutation from a small number of major genetic testing labs, although literature estimates 1,000 to 2,000 patients, suggesting underdiagnosis.
The Phase I/II study has received IND clearance and will test flat doses of 40 mg to 160 mg, about 0.5 to 2 mg/kg, across three dose-escalation cohorts before an expansion cohort. The active treatment period is 48 weeks, followed by a two-year long-term extension. Initial proof-of-concept data are expected in the second half of 2027. Preclinical single-dose animal studies showed 75% knockdown of PRKAG2, with improvements in diastolic dysfunction, reduced left atrial size, and clearance of glycogen in skeletal muscle.
CEO Kath Gallagher said the company's goal is to improve patients' lives by pioneering RNA therapeutics for the heart, while CMO Steve Hughes said the PRKAG2 G2 subunit remains permanently switched on, causing glucose to be deposited in cardiac myocytes as glycogen. Gallagher also cited high transferrin receptor expression as supporting delivery in the heart.
Atrium's second program, ATR 1086, targets phospholamban cardiomyopathy, with the most common mutation R14del. Symptoms often appear in patients' 30s and 40s, and literature estimates 2,000 to 4,000 patients. The company expects to file an IND in 2027. Animal studies showed 75% phospholamban knockdown led to 100% survival in treated mice, compared with 100% mortality in untreated mice within weeks, and maintained normal heart function while untreated mice saw ejection fractions fall to 25%.
One of two undisclosed cardiomyopathy programs is moving toward development-candidate status, with completion expected in 2026. Atrium noted that about 2 million people in the U.S. have cardiomyopathy, about half have a genetically driven disease, and only about 1% are currently genetically tested.
